Denosumab Osteoporosis

Osteoporosis - Analysis of pipeline drugs and Forecasts to 2016

This report provides key data, information and analysis on the market for osteoporosis. The report gives a comprehensive overview of market data annualized from 2001 to 2009, and forecasts on seven years to 2016. The research also includes the characterization of market opportunities, unmet needs associated with osteoporosis, competitive analysis, product profiles of key marketed products and promising drugs in the pipeline, a survey of abandoned projects, the implications competition for future market and key players in the market for osteoporosis. ( http://www.bharatbook.com/detail.asp?id=133017&rt=Osteoporosis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html )

The market for Osteoporosis Therapeutics is expected to grow significantly to 2016
The global market for osteoporosis therapy has been estimated at 9.6 billion dollars in 2009. It is expected to increase to 16.7 billion dollars at a compound annual growth rate (CAGR) of 8.2% in 2016. This significant increase is mainly due to strong current treatment options and the strong pipeline candidates. The increased prevalence of osteoporosis in the female population is the main market driver of osteoporosis and will continue to be in the future. The main reason for the increase in prevalence is due to the decreased use of hormone replacement therapy (HRT) in postmenopausal women in good health. HRT has been used to help prevent bone loss leading to osteoporosis. However, recent negative study results showing increased risk of heart attack, stroke, breast cancer and blood clots, leading to a decreased use of HRT. Therefore, population growth and population growth often combine to contribute to the increasing burden of osteoporosis.

Current treatment options are moderately successful in the meeting request
He analyzed the current market landscape and found it to be strong. Bone resorption and bone formation drugs are the two main types of drugs that are used in the treatment of osteoporosis. Bisphosphonates, calcitonin, estrogen and estrogen agonists / antagonists are the main drugs available antiresorptive market. They include alendronate (Fosamax), risedronate (Actonel), ibandronate (Bonivia), zoledronic acid (Reclast) and raloxifene (Evista). The market is currently dominated by drugs bone resorption. However, bone building drugs are being developed by researchers and are just becoming available. Eli Lilly is the only company that has two products - Evista and Forteo on the market for osteoporosis. None of these drugs are part of the bisphosphonate class. Forteo is the first and only drug bone formation available on the market.

Poor Diagnosis of the disease is a major obstacle for the osteoporosis market
The poor diagnosis of the disease is a major obstacle for the market for osteoporosis. A major reason why osteoporosis is underdiagnosed is that most vertebral fractures are asymptomatic and therefore go unnoticed by the patient and the physician. Even patients with clinically apparent fragility fracture are neglected, with less than 5% of patients with osteoporotic fractures is designated for the evaluation and medical treatment. The vast majority of patients with fragility fractures are not referred for evaluation and treatment. Studies have shown that older women and men with hip fractures do not receive drug treatment monitoring.

Pipeline Candidates should intensify competition strong future
It f.